CannBioRex Pharmaceuticals Corp is a Medical Marijuana Pharma company based in Toronto, Canada with its’ Research and Development being conducted in Oxford, UK and Jerusalem, Israel. CannBioRex is focused on the development and commercialisation of synthetic pharmaceutical grade cannabinoids for the treatment of Arthritis, Pain (Acute and Chronic), Diabetes and Obesity.
Following two decades of collaboration, Prof Sir Marc Feldmann and Prof Raphael Mechoulam founded CannBioRex to address the high unmet medical need, side effects and limitations associated with the current standards of care within our target indications.
Prof Sir Marc Feldmann is credited with the discovery and subsequent commercialization of the world’s largest selling drug class, anti-TNF, which generates over $36B USD in annual sales (2016). Anti-TNF treats Rheumatoid arthritis.
Prof Raphael Mechoulam, also known as the Godfather of the Medical Marijuana Industry, discovered THC along with two colleagues and he has elucidated various other chemical compounds, or “cannabinoids” (Prof Mechoulam coined the term), occurring in both the cannabis plant and the human body.
CannBioRex holds an exclusive worldwide license to three patents developed by Prof Raphael Mechoulam at The Hebrew University of Jerusalem. These compounds are currently being developed alongside other Intellectual Property being developed by CannBioRex at the Kennedy Institute at The University of Oxford (Prof Sir Marc Feldmann and Prof Richard Williams) and The Hebrew University Jerusalem (Prof Raphael Mechoulam and Professor Ruth Gallily).